BioCardia (BioCardia) Ending Cash Position : $1.10 Mil (As of Dec. 2023)

View and export this data going back to 1996. Start your Free Trial

What is BioCardia Ending Cash Position?

BioCardia's Ending Cash Position for the quarter that ended in Dec. 2023 was $1.10 Mil.

BioCardia's quarterly Ending Cash Position declined from Jun. 2023 ($4.31 Mil) to Sep. 2023 ($1.84 Mil) and declined from Sep. 2023 ($1.84 Mil) to Dec. 2023 ($1.10 Mil).

BioCardia's annual Ending Cash Position declined from Dec. 2021 ($12.87 Mil) to Dec. 2022 ($7.36 Mil) and declined from Dec. 2022 ($7.36 Mil) to Dec. 2023 ($1.10 Mil).

BioCardia Ending Cash Position Historical Data

The historical data trend for BioCardia's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioCardia Ending Cash Position Chart

BioCardia Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Ending Cash Position

Get a 7-Day Free Trial

5.59

21.41

12.87

7.36

1.10

BioCardia Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Ending Cash Position	Get a 7-Day Free Trial															7.36	4.86	4.31	1.84	1.10

BioCardia Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

BioCardia's Ending Cash Position for the fiscal year that ended in Dec. 2023 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	7.363	+	-6.26
	=	1.10

BioCardia's Ending Cash Position for the quarter that ended in Dec. 2023 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	1.835	+	-0.732
	=	1.10

BioCardia Ending Cash Position Related Terms

Thank you for viewing the detailed overview of BioCardia's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

BioCardia (BioCardia) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioCardia Inc (NAS:BCDA) » Definitions » Ending Cash Position

Comparable Companies

Traded in Other Exchanges

6JU:Germany

Address

320 Soquel Way, Sunnyvale, CA, USA, 94085

Website

https://www.biocardia.com

BioCardia Inc is a clinical stage regenerative medicine company. It is developing therapeutics for cardiovascular and pulmonary diseases with large unmet medical needs. The company is developing comprehensive biotherapeutic candidates for cardiac regenerative medicine namely CardiAMP and CardiALLO, with a focus on heart failure resulting from a heart attack.

Executives

Frost Phillip Md Et Al	10 percent owner	4400 BISCAYNE BLVD, MIAMI FL 33137-3227
Bill Facteau	director	C/O BIOCARDIA, INC., 320 SOQUEL WAY, SUNNYVALE CA 94085
Frost Gamma Investments Trust	10 percent owner	4400 BISCAYNE BLVD, MIAMI FL 33137
Krisztina M Zsebo	director	C/O CELLADON CORPORATION, 12760 HIGH BLUFF DRIVE, SUITE 240, SAN DIEGO CA 92130
Edward M Gillis	officer: Senior Vice President, Devices	C/O BIOCARDIA, INC., 125 SHOREWAY ROAD, SUITE B, SAN CARLOS CA 94070
Andrew Scott Blank	director	C/O BIOCARDIA, INC., 125 SHOREWAY ROAD, SUITE B, SAN CARLOS CA 94070
Jim L. Allen	director	C/O BIOCARDIA, INC., 125 SHOREWAY ROAD, SUITE B, SAN CARLOS CA 94070
Simon H Stertzer	director	C/O BIOCARDIA, INC., 125 SHOREWAY DRIVE, SUITE B, SAN CARLOS CA 94070
Peter Altman	director, officer: President and CEO	C/O BIOCARDIA INC, 125 SHOREWAY ROAD SUITE B, SAN CARLOS CA 94070
Stertzer Family Trust	10 percent owner	C/O BIOCARDIA INC, 125 SHOREWAY ROAD SUITE B, SAN CARLOS CA 94070
Kimberly Stertzer	10 percent owner	C/O BIOCARDIA INC, 125 SHOREWAY ROAD SUITE B, SAN CARLOS CA 94070
David Mcclung	officer: VP of Finance	C/O BIOCARDIA, INC., 125 SHOREWAY ROAD, SUITE B, SAN CARLOS CA 94070
Allan R Tessler	director	C/O EPOCH HOLDING CORPORATION, 640 FIFTH AVENUE, NEW YORK, NY 10019
Richard T Allen	officer: VP, Quality Assurance	C/O BIOCARDIA, INC., 125 SHOREWAY ROAD, SUITE B, SAN CARLOS CA 94070
Thomas Quertermous	director	C/O BIOCARDIA INC, 125 SHOREWAY ROAD SUITE B, SAN CARLOS CA 94070